Profiling serum bile acid glucuronides in humans: Gender divergences, genetic determinants, and response to fenofibrate

J. Trottier; M. Perreault; I. Rudkowska; C. Levy; A. Dallaire-Theroux; M. Verreault; P. Caron; B. Staels; M. C. Vohl; R. J. Straka; O. Barbier

doi:10.1038/clpt.2013.122

Profiling serum bile acid glucuronides in humans: Gender divergences, genetic determinants, and response to fenofibrate

J. Trottier
, M. Perreault
, I. Rudkowska
, C. Levy
, A. Dallaire-Theroux
, M. Verreault
, P. Caron
, B. Staels
, M. C. Vohl
, R. J. Straka
, O. Barbier

Experimental and Clinical Pharmacology

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

Glucuronidation, catalyzed by uridine 5′-diphospho- glucuronosyltransferase (UGT) enzymes, detoxifies cholestatic bile acids (BAs). We aimed to (i) characterize the circulating BA-glucuronide (BA-G) pool composition in humans, (ii) determine how sex and UGT polymorphisms influence this composition, and (iii) analyze the effects of the lipid-lowering drug fenofibrate on the circulating BA-G profile in 300 volunteers and 5 cholestatic patients. Eleven BA-Gs were determined in pre-and postfenofibrate samples. Men exhibited higher BA-G concentrations, and various genotype/BA-G associations were discovered in relevant UGT genes. The chenodeoxycholic acid-3G (CDCA-3G) concentration was associated with the UGT2B7 802C>T polymorphism. Glucuronidation assays confirmed the predominant role of UGT2B7 and UGT1A4 in CDCA-3G formation. Fenofibrate exposure increased the serum levels of five BA-G species, including CDCA-3G, and upregulated expression of UGT1A4, but not UGT2B7, in hepatic cells. This study demonstrated that fenofibrate stimulates BA glucuronidation in humans and thus reduces BA toxicity in the liver.

Original language	English (US)
Pages (from-to)	533-543
Number of pages	11
Journal	Clinical pharmacology and therapeutics
Volume	94
Issue number	4
DOIs	https://doi.org/10.1038/clpt.2013.122
State	Published - Oct 2013

Publisher link

10.1038/clpt.2013.122

Find It

Find It at U of M Libraries

Cite this

Trottier, J., Perreault, M., Rudkowska, I., Levy, C., Dallaire-Theroux, A., Verreault, M., Caron, P., Staels, B., Vohl, M. C., Straka, R. J., & Barbier, O. (2013). Profiling serum bile acid glucuronides in humans: Gender divergences, genetic determinants, and response to fenofibrate. Clinical pharmacology and therapeutics, 94(4), 533-543. https://doi.org/10.1038/clpt.2013.122

Trottier, J, Perreault, M, Rudkowska, I, Levy, C, Dallaire-Theroux, A, Verreault, M, Caron, P, Staels, B, Vohl, MC, Straka, RJ & Barbier, O 2013, 'Profiling serum bile acid glucuronides in humans: Gender divergences, genetic determinants, and response to fenofibrate', Clinical pharmacology and therapeutics, vol. 94, no. 4, pp. 533-543. https://doi.org/10.1038/clpt.2013.122

@article{bc9ea9e758c846ee8f2eb17b1024491e,

title = "Profiling serum bile acid glucuronides in humans: Gender divergences, genetic determinants, and response to fenofibrate",

abstract = "Glucuronidation, catalyzed by uridine 5′-diphospho- glucuronosyltransferase (UGT) enzymes, detoxifies cholestatic bile acids (BAs). We aimed to (i) characterize the circulating BA-glucuronide (BA-G) pool composition in humans, (ii) determine how sex and UGT polymorphisms influence this composition, and (iii) analyze the effects of the lipid-lowering drug fenofibrate on the circulating BA-G profile in 300 volunteers and 5 cholestatic patients. Eleven BA-Gs were determined in pre-and postfenofibrate samples. Men exhibited higher BA-G concentrations, and various genotype/BA-G associations were discovered in relevant UGT genes. The chenodeoxycholic acid-3G (CDCA-3G) concentration was associated with the UGT2B7 802C>T polymorphism. Glucuronidation assays confirmed the predominant role of UGT2B7 and UGT1A4 in CDCA-3G formation. Fenofibrate exposure increased the serum levels of five BA-G species, including CDCA-3G, and upregulated expression of UGT1A4, but not UGT2B7, in hepatic cells. This study demonstrated that fenofibrate stimulates BA glucuronidation in humans and thus reduces BA toxicity in the liver.",

author = "J. Trottier and M. Perreault and I. Rudkowska and C. Levy and A. Dallaire-Theroux and M. Verreault and P. Caron and B. Staels and Vohl, \{M. C.\} and Straka, \{R. J.\} and O. Barbier",

year = "2013",

month = oct,

doi = "10.1038/clpt.2013.122",

language = "English (US)",

volume = "94",

pages = "533--543",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Profiling serum bile acid glucuronides in humans

T2 - Gender divergences, genetic determinants, and response to fenofibrate

AU - Trottier, J.

AU - Perreault, M.

AU - Rudkowska, I.

AU - Levy, C.

AU - Dallaire-Theroux, A.

AU - Verreault, M.

AU - Caron, P.

AU - Staels, B.

AU - Vohl, M. C.

AU - Straka, R. J.

AU - Barbier, O.

PY - 2013/10

Y1 - 2013/10

N2 - Glucuronidation, catalyzed by uridine 5′-diphospho- glucuronosyltransferase (UGT) enzymes, detoxifies cholestatic bile acids (BAs). We aimed to (i) characterize the circulating BA-glucuronide (BA-G) pool composition in humans, (ii) determine how sex and UGT polymorphisms influence this composition, and (iii) analyze the effects of the lipid-lowering drug fenofibrate on the circulating BA-G profile in 300 volunteers and 5 cholestatic patients. Eleven BA-Gs were determined in pre-and postfenofibrate samples. Men exhibited higher BA-G concentrations, and various genotype/BA-G associations were discovered in relevant UGT genes. The chenodeoxycholic acid-3G (CDCA-3G) concentration was associated with the UGT2B7 802C>T polymorphism. Glucuronidation assays confirmed the predominant role of UGT2B7 and UGT1A4 in CDCA-3G formation. Fenofibrate exposure increased the serum levels of five BA-G species, including CDCA-3G, and upregulated expression of UGT1A4, but not UGT2B7, in hepatic cells. This study demonstrated that fenofibrate stimulates BA glucuronidation in humans and thus reduces BA toxicity in the liver.

AB - Glucuronidation, catalyzed by uridine 5′-diphospho- glucuronosyltransferase (UGT) enzymes, detoxifies cholestatic bile acids (BAs). We aimed to (i) characterize the circulating BA-glucuronide (BA-G) pool composition in humans, (ii) determine how sex and UGT polymorphisms influence this composition, and (iii) analyze the effects of the lipid-lowering drug fenofibrate on the circulating BA-G profile in 300 volunteers and 5 cholestatic patients. Eleven BA-Gs were determined in pre-and postfenofibrate samples. Men exhibited higher BA-G concentrations, and various genotype/BA-G associations were discovered in relevant UGT genes. The chenodeoxycholic acid-3G (CDCA-3G) concentration was associated with the UGT2B7 802C>T polymorphism. Glucuronidation assays confirmed the predominant role of UGT2B7 and UGT1A4 in CDCA-3G formation. Fenofibrate exposure increased the serum levels of five BA-G species, including CDCA-3G, and upregulated expression of UGT1A4, but not UGT2B7, in hepatic cells. This study demonstrated that fenofibrate stimulates BA glucuronidation in humans and thus reduces BA toxicity in the liver.

UR - https://www.scopus.com/pages/publications/84884499434

UR - https://www.scopus.com/pages/publications/84884499434#tab=citedBy

U2 - 10.1038/clpt.2013.122

DO - 10.1038/clpt.2013.122

M3 - Article

C2 - 23756370

AN - SCOPUS:84884499434

SN - 0009-9236

VL - 94

SP - 533

EP - 543

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 4

ER -

Profiling serum bile acid glucuronides in humans: Gender divergences, genetic determinants, and response to fenofibrate

Abstract

Publisher link

Find It

Other files and links

Fingerprint

Cite this